Becton, Dickinson and Company (BDX)

Revenue Breakdown

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016	Sep 30, 2015	Sep 30, 2014	Sep 30, 2013	Sep 30, 2012
Medication Delivery Solutions Revenue	4.66B	4.58B	4.43B
Specimen Management Revenue	1.95B	1.87B	1.83B
Medication Management Solutions Revenue	3.55B	3.47B	3.30B
Advanced Patient Monitoring Revenue	1.17B	1.08B	74.00M
BioPharma Systems Revenue	2.39B	2.32B	2.27B
Integrated Diagnostic Solutions Revenue	2.88B	3.71B	3.68B
Peripheral Intervention Revenue	2.08B	2.00B	1.93B
Urology and Critical Care Revenue	1.73B	1.65B	1.55B
Surgery Revenue	1.65B	1.57B	1.49B
Diagnostic Solutions Revenue	-	1.84B	1.85B
Biosciences Revenue	-	1.46B	1.51B
Revenue (Other)	-2.12B	-3.71B	-3.74B
Revenue (Total)	19.95B	21.84B	20.18B

Revenue Breakdown 2

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016	Sep 30, 2015	Sep 30, 2014	Sep 30, 2013	Sep 30, 2012
BioPharma Systems Revenue	2.39B	2.32B	2.27B
Revenue (Total)	19.95B	21.84B	20.18B

Revenue by Geography

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016	Sep 30, 2015	Sep 30, 2014	Sep 30, 2013	Sep 30, 2012
United States Revenue	12.58B	12.79B	11.66B
International Revenue	8.26B	9.05B	8.52B
Revenue (Other)	-884.00M	1.00M	-
Revenue (Total)	19.95B	21.84B	20.18B

Revenue Breakdown 3

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016	Sep 30, 2015	Sep 30, 2014	Sep 30, 2013	Sep 30, 2012
Medical Revenue	-	11.46B	10.07B
Life Sciences Revenue (Pre-FY2026 Reporting)	-	5.17B	5.19B
Interventional Revenue (Pre-FY2026 Reporting)	-	5.22B	4.98B
Revenue (Total)	19.95B	21.84B	20.18B

EBIT 2

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016	Sep 30, 2015	Sep 30, 2014	Sep 30, 2013	Sep 30, 2012
Medical Segment Operating Income	-	-	2.74B
Life Sciences Segment Operating Income (Pre-FY2026 Reporting)	-	-	1.60B
Interventional Segment Operating Income (Pre-FY2026 Reporting)	-	-	1.42B
Operating Income (Total)	1.84B	2.58B	2.40B

Data Source: Fiscal.ai Last updated: Aug 6, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 16, 2026

Data Sources Report a data error